Wyeth Europa Limited
Vanwall Road
Maidenhead
Berkshire, SL6 4UB
Tel: +44 (0)1628 692000
Fax: +44 (0)1628 692283

Wyeth

10 March 2008

Dr Eric Abadie
CHMP Chairperson
C/O The Central Information Group
The European Medicines Agency (EMEA)
7 Westferry Circus
Canary Wharf
London E14 4HB

Dear Dr Abadie

Re: Withdrawal of Pristiqs – MAA - EMEA/H/C/000794
50 mg and 100 mg prolonged release tablets

I would like to inform you that, at this point in time, Wyeth Europa Ltd has taken the decision to withdraw the application for Marketing Authorisation of Pristiqs (desvenlafaxine), 50 mg and 100 mg prolonged release tablets, which was intended to be used for treatment of vasomotor symptoms associated with the menopause.

This withdrawal is based on the following reason:

- Wyeth plans to conduct additional clinical studies that will address the CHMP's questions regarding the risk-benefit profile of Pristiqs as a treatment for vasomotor symptoms.

There are no consequences of the withdrawal on ongoing clinical trials and compassionate use programmes as none are ongoing.

We reserve the right to make further submissions at a future date for desvenlafaxine in this therapeutic indication.

Wyeth Europa Ltd
Registered in England No. 1401702
Registered Office: Huntercombe Lane South
Taplow, Maidenhead, Berkshire, SL6 0PH
A subsidiary of Wyeth, New Jersey, USA

Wyeth Europa Limited
Vanwall Road
Maidenhead
Berkshire, SL6 4UB
Tel: +44 (0)1628 692000
Fax: +44 (0)1628 692283

Wyeth

I agree for this letter to be published on the EMEA website.

Yours sincerely,
For and on behalf of Wyeth Europa Limited